Cargando…
Ustekinumab for the treatment of psoriatic arthritis: an update
Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale ran...
Autores principales: | Davari, Parastoo, Leo, Michael S, Kamangar, Faranak, Fazel, Nasim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158889/ https://www.ncbi.nlm.nih.gov/pubmed/25214798 http://dx.doi.org/10.2147/CCID.S50003 |
Ejemplares similares
-
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015) -
Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
por: Montepaone, Monica, et al.
Publicado: (2014) -
Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis
por: Gediz, Fusun, et al.
Publicado: (2021) -
Psoriatic Arthritis: An Update
por: Lloyd, Peter, et al.
Publicado: (2012) -
Cutaneous and Mucosal Lichen Planus: A Comprehensive Review of Clinical Subtypes, Risk Factors, Diagnosis, and Prognosis
por: Gorouhi, Farzam, et al.
Publicado: (2014)